Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Interest & Investment Income (2020 - 2022)

Terns Pharmaceuticals filings provide 3 years of Interest & Investment Income readings, the most recent being $1.3 million for Q4 2022.

  • Quarterly Interest & Investment Income rose 2314.55% to $1.3 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2022, up 1141.18% year-over-year, with the annual reading at $14.6 million for FY2025, 9.8% up from the prior year.
  • Interest & Investment Income hit $1.3 million in Q4 2022 for Terns Pharmaceuticals, up from $499000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.3 million in Q4 2022 and bottomed at $1000.0 in Q3 2020.
  • Average Interest & Investment Income over 3 years is $194583.3, with a median of $52500.0 recorded in 2020.
  • Peak annual rise in Interest & Investment Income hit 4800.0% in 2021, while the deepest fall reached 78.0% in 2021.
  • Terns Pharmaceuticals' Interest & Investment Income stood at $2000.0 in 2020, then soared by 2650.0% to $55000.0 in 2021, then skyrocketed by 2314.55% to $1.3 million in 2022.
  • Per Business Quant, the three most recent readings for TERN's Interest & Investment Income are $1.3 million (Q4 2022), $499000.0 (Q3 2022), and $214000.0 (Q2 2022).